Music to prevent delirium during neurosurgery (MUSYC) Clinical trial: a study protocol for a randomised controlled trial

Pablo R Kappen1,1, Johannes Jeekel2,3, Clemens M F Dirven1,1, M Klimek4,4, Steven A Kushner5, Robert-Jan Osse5, Michiel Coesmans5, Marten J Poley6,7, Arnaud J P E Vincent1

ABSTRACT

Introduction Delirium is a neurocognitive disorder characterised by an acute and temporary decline of mental status affecting attention, awareness, cognition, language and visuospatial ability. The underlying pathophysiology is driven by neuroinflammation and cellular oxidative stress. Delirium is a serious complication following neurosurgical procedures with a reported incidence varying between 4% and 44% and has been associated with increased length of hospital stay, increased amount of reoperations, increased costs and mortality. Perioperative music has been reported to reduce preoperative anxiety, postoperative pain and opioid usage, and attenuates stress response caused by surgery. We hypothesize that this beneficial effect of music on a combination of delirium eliciting factors might reduce delirium incidence following neurosurgery and subsequently improve clinical outcomes.

Methods This protocol concerns a single-centred prospective randomised controlled trial with 6 months follow-up. All adult patients undergoing a craniotomy at the Erasmus Medical Center in Rotterdam are eligible. The music group will receive recorded music through an overear headphone before, during and after surgery until postoperative day 3. Patients can choose from music playlists, offered based on music importance questionnaires administered at baseline. The control group will receive standard of clinical care. Delirium is assessed by the Delirium Observation Scale and confirmed by a delirium-expert psychiatrist according to the DSM-5 criteria. Risk factors correlated with the onset of delirium, such as cognitive function at baseline, preoperative anxiety, perioperative medication use, depth of anaesthesia and postoperative pain, and delirium-related health outcomes such as length of stay, daily function, quality of life (ie, EQ-5D, EORTC questionnaires), costs and cost-effectiveness are collected.

Ethics and dissemination This study is being conducted in accordance with the Declaration of Helsinki. The Medical Ethics Review Board of Erasmus University Medical Center Rotterdam, The Netherlands, approved this protocol. Results will be disseminated via peer-reviewed scientific journals and conference presentations.

Trial registration numbers NL8503 and NCT04649450.

Strengths and limitations of this study

► This study is the first randomised controlled trial evaluating the effects of recorded music on postoperative delirium in a neurosurgical cohort.
► To our knowledge, this is the largest study assessing the effects of music on delirium.
► Both the short-term and longer-term delirium-associated clinical outcomes will be evaluated, as either data during hospitalisation and follow-up data until 6 months postoperatively, will be collected.
► Due to the nature of the intervention, blinding of the patients and data collectors was not possible, which is a limitation. However, we expect a low risk of bias in the clinical assessment, as the onset of delirium is not considered a subjective outcome.

INTRODUCTION

Delirium is characterised by an acute and temporary decline in mental status affecting attention, awareness, cognition, language and visuospatial ability. This decline is caused by dysregulation of neuronal activity secondary to several pathophysiological disturbances. Surgery within the brain parenchyma evokes an inflammatory reaction resulting in the formation of oedema and decrease of vascular permeability with impaired oxygenation of nearby tissue resulting in the generation of oxidative stress. Hypotheses describing the pathophysiology of delirium rely on neuroinflammatory and oxidative reactions within the brain. Considering this, it is plausible that neurosurgical patients are in particular vulnerable to developing postoperative delirium and that the incidence of delirium in this population is high.

Incidence rates of postoperative delirium after intracranial surgery vary between 4% and 44% depending on the type of surgery, such as major neurovascular reporting higher
incidence rates and method of delirium assessment, such as short follow-up duration resulting in lower incidence rates. Delirium often causes a traumatic experience for the patient and his or her relatives. Delirium also leads to up to twice the length of hospital stay, twice the intensity of nursing hours, almost twice the amount of reoperations with additional exposure to complications, three times the costs and more than five times higher mortality risk. Delirium can cause in the long term a decline in subjective memory, cognitive decline and increase the chance of developing dementia. These observations warrant the search for preventive therapies for postoperative delirium.

Several preventive pharmacological interventions for occurrence of postoperative delirium have been studied. Pharmacological interventions, targeted at the psychotic symptoms such as olanzapine or haloperidol, at the sleep-wake cycle such as melatonin, or lowering sedation levels through Bispectral Index (BIS), were either ineffective or non-reproducible in preventing delirium after surgery. Furthermore, most of these drugs may have severe side effects.

Non-pharmacological multicomponent approaches such as the Hospital Elder Life Programme or the Perioperative Optimisation of Senior Health programme are promising, showing a relative reduction of delirium in 36%–77%. However, success of these multicomponent strategies is dependent on the adherence while implementation is challenging and not always adjusted to the feasibility for nurse or patients' needs.

Recorded music is effective in reducing preoperative anxiety, postoperative pain and its stress response induced by surgery. Moreover, lower doses of opioids and sedatives are required when music around surgery is applied with the strongest effect of music in case of patients-own choice irrespective of own music or from preselected playlists. These positive effect on a combination of delirium-eliciting factors might contribute to a reduction of postoperative delirium.

Three studies have been published on the effect of music as a sole intervention on the occurrence of postoperative delirium. One is a five-armed trial with a total of 126 patients (approximately 25 per arm) in which no significant effect was seen. However, this study lacked a solid power analysis. The second trial had no delirium in either the music and control group due to their exclusion criteria and therefore no effect could be demonstrated. The third trial randomised 22 patients and reported significant better outcome in the music group. In none of these trials, the music selection was based on patient’s preference. In conclusion, although suggestive, currently no strong evidence exists on the possible beneficial effect of music on delirium.

Furthermore, evidence on the effects of music interventions on delirium-related health outcomes such as length of stay, daily functioning, costs, quality of life and cost-effectiveness is lacking. This is a significant knowledge gap, as these truly represent clinically relevant outcome measures for patient and society.

Therefore, this article reports on a randomised control trial to assess the effect of music in the prevention of postoperative delirium in neurosurgical patients.

**METHODS AND ANALYSIS**

**Study design**

This study is a randomised controlled trial with two study arms, designed to compare the effects on postoperative delirium, of perioperative recorded music intervention in addition to standard care (intervention group) versus standard care (control group)—prior, during and after a craniotomy. Figure 1 shows the flow diagram of the progress through the trial phases of the two study groups. We will include 189 adults at the Neurosurgery department of the Erasmus Medical Center (Erasmus MC) in Rotterdam. Ethical Committee approval was obtained in April 2020, the first patient was included in July 2020 and July 2022 is the anticipated end date of inclusion. This study protocol followed the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (see SPIRIT checklist in online supplemental material) and the Consolidated Standards of Reporting Trials (CONSORT) guidelines for non-pharmacological treatments.

**Randomisation, blinding and treatment allocation**

The random allocation sequence will be computer generated using an online software program or website (ALEA; FormVision, Abcoude, The Netherlands) run by the executing researcher after obtaining informed consent. Randomisation will be in a 1:1 ratio and stratified per type of disease characteristic (ie, ‘neuro-oncology’, ‘neurovascular’, ‘traumatic brain injury’, ‘infectious’) and age (ie, ‘younger than 60 years’, ‘60 years or older’). Variable block sizes will be used; in each block both groups will be represented equally. The web-based programme will be secured and only members of the study staff will have login credentials.

Patients participating in the study cannot be blinded due to the nature of the treatment. Selective blinding of the clinicians and data collectors is unsecure while patients might report their experience when undergoing the (music/control) intervention. Hence, to prevent misleading conclusions an unblinded design was chosen. In our view, this is not too much of a limitation, since the primary outcome of this study (ie, the onset of delirium) can be assessed objectively.

As the intervention is without risks and cannot be blinded, it will in no case be necessary to break the randomisation code. Data collection and intervention administration (conducted by the treating nurses and consulting psychiatrist) and randomisation and final analysis (conducted by the executing researcher) were separated but not masked from each other.
Interventions

Participants in the intervention group (ie, music group) receive an overear headphone and a tablet with access to a platform with different music playlists. These lists are based on personal preference gathered from questionnaires at baseline assessing the role (ie, just listening vs playing instruments), importance (ie, through a Visual Analogue Scale (VAS) from 0 to 100) and preference of music (ie, on genre) per patient. These preselected playlists are categorised based on genre (jazz, blues, classic, electronic, pop, 60s, 70s, 80s, etc), country or artist, are either custom made or composed by our research group from earlier trials and have a minimum duration of 180 min to prevent repetition of songs within the same music session. The first 30 min of music, administered by the treating nurse, is given the day of operation with the overear headphones while awaiting surgery. Once in the operating room they will receive in-ear earphones after intubation, compatible with the Mayfield clamp and site of operation. The intraoperative music intervention, in accordance with the preoperative choice of music, will be continued during the surgical procedure and discontinued just before detubation. Although patients might not remember this music session, we chose for music during general anaesthesia as a significant decrease in pain and anxiety has been reported in surgical patients when receiving intra-operative music. The intraoperative music session is continuous and the duration depends on the duration of surgery and will be documented. After surgery, during recovery at the postoperative care unit another 30 min of recorded music through overear headphones will be administered. Subsequently, participants will receive 30 min of recorded music twice a day for the following three postoperative days as music is currently investigated as preventive therapy and onset of postoperative delirium has been reported in the first 3–5 days after intracranial surgery.

The control group will not receive headphone music and will be treated according to standard care. We did not choose for overear headphones—without music or other auditory signals—in our control group as this is considered an intervention requiring another study arm, which we deemed unfeasible. It would be an interesting opportunity for future research to include other comparison and control groups (exposed to other auditory input or silence), which could also generate more options for blinding the clinicians and data collectors.

All participating subjects in this study will be requested to refrain from listening to music through headphone during the first three postoperative days, apart from the planned intervention. Music other than from the headphone (eg, television) is allowed in either the music or control group but patient or a family member is asked to report this.
Patients in either group, besides the screening tools for our primary and secondary outcomes, will receive standard clinical care and will not be restricted from any treatments whatsoever.

**Outcome parameters**

The primary outcome measure is presence or absence of postoperative delirium within the first five postoperative days. All participating patients on the ward will be screened daily by the treating nurse using the Delirium Observation Screening (DOS) scale, a validated 13-item delirium screening tool which is already current practice at the Neurosurgical ward in the Erasmus MC. In case of raised suspicion by the DOS a psychiatrist is consulted to confirm or reject clinical diagnosis of delirium based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria.1

Secondary outcome parameters include risk factors and health outcomes, which substantiate the effect of music on delirium and evaluate its clinical implications for patient and society:

- Severity and duration of delirium. In case of positive delirium, its severity will be assessed using the Delirium Rating Scale-revised-98. A DOS score of lower than 3 during 24 hours will be considered as a ‘faded out’ delirium and number of days from onset until end will be documented.
- Preoperative anxiety assessed with the VAS-anxiety. This 11-point scale, in which 0 implies no anxiety and 10 the worst anxiety possible, is easy to use, highly correlated with the State-Trait Anxiety Inventory, and is assessed while awaiting surgery. In case of visual impairment, caused by the neurological disease, VAS will be exchanged for Numeric Rating Scale (NRS).49–52
- Activation of the parasympathetic nervous system, before and after surgery, using the heart rate variability (HRV). The HRV, the variation in the time interval between adjacent heartbeats related to parasympathetic influences, is measured through ECG recordings while awaiting and when recovering from surgery.53
- Depth of anaesthesia is registered with BIS, which signals Electroencephalography (EEG) brain activity displayed into numerical values. The BIS is often used to guide during anaesthesia but its feasibility and implications during neurosurgical operations is still unknown.54 55
- Perioperative medication use, such as opioids, benzodiazepines and antipsychotic drugs, will be extracted from the electronic patient files.
- Postoperative pain, assessed using the validated 11-point NRS-scale, in which 0 implies no pain and 10 the worst pain possible.56
- Postoperative complications defined as an adverse event within 2 weeks after surgery resulting in prolongation of current admission, new treatment (ie, reoperations) or death.
- Hospital length of stay in days defined as the day of admission until the actual day of discharge.
- Cognitive function assessed with the Montreal Cognitive Assessment tool at baseline, 3 and 6 months.57
- Daily function expressed in Karnofsky Performance Scale and modified Ranking Scale.58–60 This is assessed at baseline, 6 weeks, 3 and 6 months after surgery.
- Mortality and readmission rate will be evaluated during the follow-up at 6 weeks, 3 and 6 months.
- Health-related quality of life with the European Organisation For Research And Treatment Of Cancer (EORTC)-C30 and the EORTC-BN20 questionnaires at baseline and during the follow-up at 6 weeks, 3 and 6 months.
- Music importance (ie, based on a VAS in which 0 implies no importance at all and 100 the most imaginable importance), preference (ie, chosen per genre) and the role of music (ie, just listening/active playing) is administered at baseline. Moreover patient satisfaction, whether patient received music or not, is assessed at 6 weeks after discharge.51
- Economic evaluation; see below for further details.

**Eligibility criteria**

Potential subjects visiting the outpatient clinic or admitted to the neurosurgical ward will be informed about our study. A member of the research team undertakes the initial screening for eligibility. In order to be eligible to participate in this study, a subject must meet all of the following inclusion criteria:

- Patients undergoing a craniotomy.
- Adult patients (ie, age 18 years or more).
- Sufficient knowledge of the Dutch language to understand the study documents in the judgement of the attending physician or researcher.
- Provision of written informed consent by patient or legal representative.

A potential subject who meets any of the following criteria will be excluded from participation in this study:

- Impaired awareness before surgery (ie, motoric less than 6 in the Glasgow Coma Scale).
- Planned postoperative ICU admission (ie, with prolonged sedation and mechanical ventilation).
- Suspected delirium (defined as fluctuating awareness) before surgery.
- Current antipsychotic treatment.
- Patients undergoing surgery impeding supply of music (eg, surgical translabyrinthine approach, awake surgery).
- Severe bilateral hearing impairment, defined as no verbal communication possible.
- Known musicogenic epilepsy (ie, seizure provoked when hearing a specific type of sound or musical stimuli).
- Current participation in other clinical trials interfering with results.
Sample size
We expect an incidence of delirium in our control group of 30%. This is based on literature documenting incidence of delirium in neurosurgical patients in a northern European population of 29%–33%. We will, therefore, consider the intervention clinically relevant if a relative reduction of 60%, corresponding to an absolute reduction of 18%, is achieved. Assuming a power of 80%, a two-sided p value of 0.05, and 1:1 randomisation, a sample size of 90 patients per arm would be required. We expect a lost to follow-up of 5% and will, therefore, include 189 patients.

Inclusion period
We expect 50% of the craniotomy patients not to be eligible due to inclusion or exclusion criteria given above. This leaves 240 eligible patients each year, taking into account that approximately 480 craniotomies are conducted at the Erasmus MC in Rotterdam each year. In 30% of these cases, it concerns emergency operations and we do not expect to be able to include many of these patients. Considering this, we would in theory therefore need 14 months for inclusion. Hence, we would plan 24 months of inclusion time taking into account all the logistic challenges. In practice, this comes down to one or two inclusions each week.

Statistical analysis
All analyses will be conducted according the intention-to-treat principle, that is, patients will be analysed according to the treatment arm they were assigned to, irrespective of the treatment they actually received. The primary endpoint in a patient will be the occurrence of a DOS score 3 or higher subsequently confirmed with the DSM-5 by a psychiatrist. Those patients will be considered as event, all other patients will be considered as non-event. The proportion of patients with an event will be compared between the randomisation arms using univariate and multivariate logistic regression analysis, that is, the OR with 95% CI will be calculated. A two-sided p value of 0.05 or less will be considered statistically significant. All other analyses will be exploratory and therefore as hypothesis-generating only.

Economic evaluation
Taking a societal perspective, we will analyse the cost-effectiveness of the music intervention versus ‘standard care’, using the techniques of a trial-based cost-effectiveness analysis and cost-utility analysis. Established methods for economic evaluations in healthcare will be used. The analysis will include both medical and non-medical costs. Medical costs include all the costs of hospital admissions, surgeries, diagnostic imaging, laboratory findings and consultations. The cost analysis will include costs of treating adverse consequences of delirium (such as falls and post-traumatic stress) and will extend beyond the initial hospital admission, including visits to the outpatient department, readmissions, nursing home admissions, medications and consultations with psychiatrists. To collect data on healthcare use, both the hospital’s electronic information system and data from the iMTA Medical Consumption Questionnaire (administered to the patients at the follow-up visits) will be used. These data will then be combined with unit costs to generate patient-level costs. Non-medical costs will comprise costs of lost productivity. After all, it is expected that patients in the intervention group may resume their (paid and/or unpaid) work earlier, as the occurrence of delirium declines. Productivity losses will be measured and valued using the iMTA Productivity Cost Questionnaire. Finally, for the patients in the intervention group, the costs of the music intervention itself (ie, headphones, earphones and sound equipment) will be added.

To measure the effects of the intervention, the economic evaluation will consider the occurrence of delirium (as defined above) and quality-adjusted life-years (QALYs). The calculation of QALYs will be based on survival data and on the EuroQol (EQ)-5D questionnaire. The EQ-5D is a generic, preference-based quality of life measure, comprising five dimensions of health, that allows for the calculation of QALYs. The EQ-5D will be administered at base line and at 6 weeks and 3 and 6 months follow-up.

Then, incremental cost-effectiveness ratios (ICERs) will be calculated by dividing the difference in costs between the groups by the difference in effects, unless one treatment dominates the other (ie, has lower costs and greater effects). The ICERs will be expressed as incremental costs per case of delirium prevented and incremental costs per QALY gained. Uncertainty in the estimation of the ICERs will be illustrated through cost-effectiveness planes (via bootstrapping). Cost-effectiveness acceptability curves will be calculated showing the probability of the intervention being cost-effective compared with ‘standard care’ as a function of society’s willingness-to-pay for a QALY gained. The time horizon of the analysis will be the 6 months follow-up period. As a result, discounting of future costs and benefits will not be required. Sensitivity analysis will be performed to assess the robustness of the analysis to certain assumptions.

Patient and public involvement
Patients are involved in the composition of the music playlists, as these are based on their music preference, the role music plays in their life (ie, whether they are musician/just listen to music) and the importance of music. The results of our trial will be disseminated to the participating patients through a letter after publication.

Trial monitoring
Based on the small chance of damage due to the intervention, our risk is expected to be negligible (risk class...
A). Monitoring will be conducted for quality assurance of data, patient inflow, meeting of inclusion and exclusion criteria, informed consent, compliance, patient safety, study procedures and source document verification in compliance with the monitoring plan for risk class A (negligible risk).

Our monitor will be an independent qualified researcher who completed a Good Clinical Practice training course. Results, conclusion and advice will be recorded in the monitor report and stored for at least 15 years.

All investigators and study staff will be responsible for reporting adverse effects to the coordinating investigator. The coordinating investigator or principal investigator will report adverse events to the Medical Ethics Review Board in accordance with the ethics committee adverse event reporting procedures. The coordinating investigator and the principal investigator are responsible for adherence to all ethical committee rules and guidelines and for the accuracy and completeness of all forms, entries and informed consent.

Data management
Data will be handled confidentially in compliance with the EU General Data Protection Regulation and the Dutch Act on Implementation of the General Data Protection Regulation (Dutch: Uitvoeringswet Algemene Verordening Gegevensbescherming). Each subject will receive an identification (ID) code which will be based on a random number produced by the randomisation software ALEA and the database tracing towards the patients’ ID will be stored separately. Any information on paper collected during this study will be placed in a research folder, which will be filed in locked cabinets in research offices at the Erasmus MC. Any electronic information acquired during the research period will be stored in OpenClinica, a secured and Erasmus MC approved storage programme which tracks all the changes applied in the database and freezes data when inclusion and data check has been done. Only the study staff will have access to the research data.

ETHICS AND DISSEMINATION

Ethics
The study protocol has been reviewed by the Medical Ethics Review Board of the Erasmus MC in Rotterdam on 9 March 2020 and is not subject to the Medical Research Involving Human Subjects Act (Dutch: Wet medisch-wetenschappelijk onderzoek met mensen / WMO). This study is being conducted according to the principles of the Declaration of Helsinki (6th WMA General Assembly, Fortaleza, Brazil, October 2013).

Benefits and risks assessment
Listening to music might be experienced as pleasant. During the informed consent process, it will be made clear that participation might not have clear direct benefits to the patient, and that refusal to participate will not have impact on the care received by any of the medical staff.

Recent meta-analysis showed no side effects of recorded music through headphones. Hypothetically there is a chance of hearing damage—with subsequent tinnitus—which will be minimalised by setting a volume limit of 60 dB on each tablet, which is the advised loudness of a music intervention in medical care. Moreover, participants might be upset of being refrained from music when allocated in the control group. Lastly, communicating at the clinician might be complicated during the music session, especially in immobile patients.

All adverse events will be documented. We expect no intervention-related serious adverse events.

Dissemination
The research team is committed to full disclosure of the results of the trial. Findings will be reported in accordance with CONSORT guidelines and we aim to publish in high-impact journals. Given the multitude of outcome parameters, results will be divided over several papers. The funder will take no role in the analysis or interpretation of results.

Author affiliations
1Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands
2Neuroscience, Erasmus MC, Rotterdam, The Netherlands
3Surgery, Erasmus MC, Rotterdam, The Netherlands
4Anesthesiology, Erasmus MC, Rotterdam, The Netherlands
5Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands
6Pediatric Surgery, Erasmus MC Sophia, Rotterdam, The Netherlands
7Medical Technology Assessment (iMTA), Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands

Correction notice This article has been corrected since it was first published. The middle name for the author SA Kushner and PR Kappen has been added.

Contributors Each author has contributed significantly to, and is willing to take public responsibility for, one or more aspects of the study. AJPEV, CMFD, JJ and PK conceived the study idea. PK coordinated the research protocol and wrote the first draft of the manuscript. JJ, CMFD, MK, SAK, R-JO, MC, MJP and AJPEV critically revised the manuscript. All authors have seen and approved the final version of the manuscript being submitted. The article is the authors’ original work, has not received prior publication and is not under consideration for publication elsewhere.

Funding This research is funded with the Erasmus MC Efficiency Grant (Grant number: 19105) by the Erasmus Medical Centre, Rotterdam, The Netherlands.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.